Compound class:
Synthetic organic
Comment: Neoceptin-4 is a synthetic Toll-like receptor 4 (TLR4) agonist [2]. It bears no structural similarity with the endogenous ligand for TLR4, LPS. This is one of the compounds claimed in patent WO2014131023 [1] in which the neoceptin's action as an immune system adjuvant is claimed. Neoceptins are claimed for their ability to elicit an immune response via the TLR4, without the toxicity exhibited by LPS.
|
|
References |
1. Beutler B, Boger DL. (2014)
Neoseptins: small molecule adjuvants. Patent number: WO2014131023 A1. Assignee: The Scripps Research Institute, The Board Of Regents Of The University Of Texas System. Priority date: 25/02/2013. Publication date: 28/08/2014. |
2. Morin MD, Wang Y, Jones BT, Su L, Surakattula MM, Berger M, Huang H, Beutler EK, Zhang H, Beutler B et al.. (2016)
Discovery and Structure-Activity Relationships of the Neoseptins: A New Class of Toll-like Receptor-4 (TLR4) Agonists. J Med Chem, 59 (10): 4812-30. [PMID:27050713] |